Related Experiment Video
Updated: Oct 17, 2025

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
Published on: June 27, 2015
TRPC5 Channel Inhibition Protects Podocytes in Puromycin-Aminonucleoside Induced Nephrosis Models
Yiming Zhou1,2, Choah Kim2, Juan Lorenzo B Pablo2
1Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Abstract:
Podocyte injury and the appearance of proteinuria are key features of several progressive kidney diseases. Genetic deletion or selective inhibition of TRPC5 channels with small-molecule inhibitors protects podocytes in rodent models of kidney disease, but less is known about the human relevance and translatability of TRPC5 inhibition. Here, we investigate the effect of TRPC5 inhibition in puromycin aminonucleoside (PAN)-treated rats, human iPSC-derived podocytes, and kidney organoids. We first established that systemic administration of the TRPC5 inhibitor AC1903 was sufficient to protect podocyte cytoskeletal proteins and suppress proteinuria in PAN-induced nephrosis rats, an established model of podocyte injury. TRPC5 current was recorded in the human iPSC-derived podocytes and was blocked by AC1903. PAN treatment caused podocyte injury in human iPSC-derived podocytes and kidney organoids. Inhibition of TRPC5 channels reversed the effects of PAN-induced injury in human podocytes in both 2D and 3D culture systems. Taken together, these results revealed the relevance of TRPC5 channel inhibition in puromycin-aminonucleoside induced nephrosis models, highlighting the potential of this therapeutic strategy for patients.
Insights
TRPC5 channel inhibition protects podocytes from injury and reduces proteinuria in kidney disease models. This study confirms the therapeutic potential of TRPC5 inhibitors for treating progressive kidney diseases.
Area of Science:
- Nephrology
- Molecular Biology
- Pharmacology
Background:
- Podocyte injury and proteinuria characterize progressive kidney diseases.
- TRPC5 channel inhibition shows promise in rodent models, but human relevance is unclear.
Purpose of the Study:
- Investigate TRPC5 inhibition effects in PAN-induced nephrosis rats, human iPSC-derived podocytes, and kidney organoids.
- Assess the therapeutic potential of TRPC5 inhibition for kidney disease.
Main Methods:
- Administered TRPC5 inhibitor AC1903 to PAN-treated rats.
- Recorded and blocked TRPC5 currents in human iPSC-derived podocytes.
- Induced podocyte injury using PAN in 2D and 3D human cell/organoid cultures.
Main Results:
- AC1903 protected podocyte cytoskeletal proteins and suppressed proteinuria in rats.
- TRPC5 inhibition reversed PAN-induced podocyte injury in human cells and organoids.
- TRPC5 channel activity was confirmed and blocked in human podocytes.
Conclusions:
- TRPC5 channel inhibition is relevant for puromycin aminonucleoside-induced nephrosis.
- TRPC5 inhibition demonstrates therapeutic potential for progressive kidney diseases.
More Related Videos
Related Concept Videos
Drug Elimination by Renal Route: Tubular Secretion
Renal Drug Excretion: Tubular Secretion

